Multimodale und palliative Therapie des Bronchialkarzinoms

  • K. Schulze


Aufgrund seiner Häufigkeit und der schlechten Prognose stellt die Therapie des Bronchialkarzinoms eine große Herausforderung an Chirurgen, Chemo- und Strahlentherapeuten dar.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Drings P, Manegold C (2000) Differentialindikation zur Induktionstherapie bei nichtkleinzelligen Lungentumoren. Chirurg 71: 1466–1473PubMedCrossRefGoogle Scholar
  2. 2.
    Elias AD, Herdon J, Kumar P, Shugarbaker D, Green MR et al. (1997) A phase III comparison of „best local-regional therapy“ with or without chemotherapy for stage IIIA T2-3 N2 non-small cell lung cancer: preliminary results. Proc Am Soc Clin Oncol 16: 448 (A1611)Google Scholar
  3. 3.
    Furuse K, Furuoka M, Kawahara M et al. (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17: 2692–2699PubMedGoogle Scholar
  4. 4.
    Juretic A, Sobat H, Samija M (1999) Combined modality therapy of non-small cell lung cancers. Ann Oncol 10(Suppl 6): 93–98PubMedCrossRefGoogle Scholar
  5. 5.
    Keller SM, Adak S, Wagner H et al. (2000) A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 343: 1217–1222PubMedCrossRefGoogle Scholar
  6. 6.
    Miyazawa T, Yamakido M, Ikeda S et al. (2000) Implantation of ultraflex nitinol stents in malignant tracheobronchial stenoses. Chest 118: 959–965PubMedCrossRefGoogle Scholar
  7. 7.
    Pritchard RS, Anthony SP (1996) Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced unresectable, non-small cell lung cancer: a meta-analysis. Ann Intern Med 125: 723–728PubMedGoogle Scholar
  8. 8.
    Pirker R, Malayeri R, Huber H (1999) Adjuvant and induction chemotherapy in non-small cell lung cancer. Ann Oncol 10(Supp. 6): 71–76PubMedCrossRefGoogle Scholar
  9. 9.
    Roth JA, Fossella F, Komaki R, Ryan MB (1994) A randomised trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage III nonsmall cell lung cancer. J Natl Cancer Inst 86: 673–680PubMedCrossRefGoogle Scholar
  10. 10.
    Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M (1999) Continuous, hyperfractionated, accelerated radiotherapy (CHART) vs conventional radiotherapy in NSCLC: Mature data from the randomised multicentre trial. Radiother Oncol 52: 137–148PubMedCrossRefGoogle Scholar
  11. 11.
    Sause W, Kolessar P, Taylor S IV et al. (2000) Final results of phase III trial in regionally advanced unresectable nonsmall cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117: 358–364PubMedCrossRefGoogle Scholar
  12. 12.
    Seijo LM, Sterman DH (2001) Interventional pulmology. N Engl J Med 344: 740–749PubMedCrossRefGoogle Scholar
  13. 13.
    Simoff MJ (2001) Endobronchial management of advanced lung cancer. Cancer Control 8: 373–343Google Scholar
  14. 14.
    Steward IA, Pignon JP (1995) Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group (IA Stewart, JP Pignon). BMJ 311: 889–890CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • K. Schulze

There are no affiliations available

Personalised recommendations